**TABLES**

**TABLE 1- Age distribution:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.NO** | **AGE RANGE IN YEARS** | **NO OF PATIENTS IN EACH RANGE** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **<30 Years** | **1** | **151** | **0.6%** |  |
| **2** | **31-50** | **38** | **151** | **25.2%** |  |
| **3** | **51-75** | **98** | **151** | **64.9%** |  |
| **4** | **76-95** | **14** | **151** | **9.3%** |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **S.NO** | **AGE RANGE IN YEARS** | **NO OF PATIENTS IN EACH RANGE** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** |
| **1** | **<30 Years** | **1** | **151** | **0.6%** |
| **2** | **31-40** | **7** | **151** | **4.6%** |
| **3** | **41-50** | **31** | **151** | **20.6%** |
| **4** | **51-60** | **48** | **151** | **31.8%** |
| **5** | **61-70** | **37** | **151** | **24.5%** |
| **6** | **71-80** | **27** | **151** | **17.9%** |

**TABLE 2- Gender distribution:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.NO** | **GENDER** | **NO OF PATIENTS IN EACH RANGE** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Male** | **84** | **151** | **56.6%** |  |
| **2** | **Female** | **67** | **151** | **44.4%** |  |

**TABLE 3- Occupation distribution:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.NO** | **Occupation** | **NO OF PATIENTS IN EACH RANGE** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
|  |
| **1** | **Agriculture** | **29** | **151** | **19.24%** |  |
| **2** | **Business** | **15** | **151** | **9.93%** |  |
| **3** | **chief pharmacist** | **1** | **151** | **0.66%** |  |
| **4** | **clerk** | **2** | **151** | **1.32%** |  |
| **5** | **Driver** | **6** | **151** | **3.97%** |  |
| **6** | **Electrician** | **2** | **151** | **1.32%** |  |
| **7** | **ex-serviceman** | **1** | **151** | **0.66%** |  |
| **8** | **Housewife** | **65** | **151** | **43.05%** |  |
| **9** | **IT engineer** | **1** | **151** | **0.66%** |  |
| **10** | **mechanic** | **1** | **151** | **0.66%** |  |
| **11** | **Office Assistant** | **1** | **151** | **0.66%** |  |
| **12** | **Plumber** | **1** | **151** | **0.66%** |  |
| **13** | **Retired** | **9** | **151** | **5.98%** |  |
| **14** | **Shopkeeper** | **1** | **151** | **0.66%** |  |
| **15** | **Student** | **1** | **151** | **0.66%** |  |
| **16** | **Tailor** | **2** | **151** | **1.32%** |  |
| **17** | **Teacher** | **4** | **151** | **2.65%** |  |
| **18** | **Watchman** | **2** | **151** | **1.32%** |  |
| **19** | **Worker** | **7** | **151** | **4.62%** |  |

**TABLE 4 - co-morbidity distribution:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Comorbidities** | **NO OF PATIENTS IN EACH RANGE** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **Asthma** | **1** | **151** | **0.66** |  |
| **COPD** | **1** | **151** | **0.66** |  |
| **Diabetes + Anaemia** | **1** | **151** | **0.66** |  |
| **Diabetes + Asthma + Previous CAD** | **1** | **151** | **0.66** |  |
| **Diabetes + Previous CAD** | **5** | **151** | **3.31** |  |
| **Diabetes + Previous CAD + Anaemia** | **1** | **151** | **0.66** |  |
| **Diabetes + Previous CAD + TB** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypertension** | **27** | **151** | **17.88** |  |
| **Diabetes + Hypertension + Anaemia** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypertension + Asthma** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypertension + TB** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypertension + Hypothyroidism** | **3** | **151** | **1.99** |  |
| **Diabetes + Hypertension + Hypothyroidism + Previous CAD** | **12** | **151** | **7.95** |  |
| **Diabetes + TB** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypothyroidism** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypothyroidism + AKI + Previous CAD** | **1** | **151** | **0.66** |  |
| **Diabetes + Hypothyroidism +Heart Disease** | **2** | **151** | **1.32** |  |
| **Diabetes** | **13** | **151** | **8.61** |  |
| **Previous CAD** | **5** | **151** | **3.31** |  |
| **Hypertension + Asthma** | **6** | **151** | **3.97** |  |
| **Hypertension + Previous CAD** | **8** | **151** | **5.30** |  |
| **Hypertension + CKD** | **1** | **151** | **0.66** |  |
| **Hypertension + Hypothyroidism** | **3** | **151** | **1.99** |  |
| **Hypertension + Hypothyroidism + Previous CAD** | **1** | **151** | **0.66** |  |
| **Hypertension** | **29** | **151** | **19.21** |  |
| **TB** | **1** | **151** | **0.66** |  |
| **Hypothyroidism + Previous CAD** | **1** | **151** | **0.66** |  |
| **Hypothyroidism** | **1** | **151** | **0.66** |  |
| **Nil** | **21** | **151** | **13.91** |  |

**TABLE 5 – AVERAGE NUMBER OF DRUGS PER PRESCRIPTION:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.NO** | **NO OF DRUGS PER PRESCRIPTION** | **NO OF PATIENTS IN EACH RANGE** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
|  |
| **1** | **4** | **7** | **151** | **4.62%** |  |
| **2** | **5** | **12** | **151** | **7.95%** |  |
| **3** | **6** | **17** | **151** | **11.26%** |  |
| **4** | **7** | **25** | **151** | **16.56%** |  |
| **5** | **8** | **21** | **151** | **13.91%** |  |
| **6** | **9** | **16** | **151** | **10.60%** |  |
| **7** | **10** | **17** | **151** | **11.26%** |  |
| **8** | **11** | **13** | **151** | **8.61%** |  |
| **9** | **12** | **7** | **151** | **4.62%** |  |
| **10** | **13** | **9** | **151** | **5.98%** |  |
| **11** | **14** | **5** | **151** | **3.31%** |  |
| **12** | **16** | **1** | **151** | **0.66%** |  |
| **13** | **18** | **1** | **151** | **0.66%** |  |

**TABLE 6 – Antibiotics distribution:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **PRESCRIPTION** | **NUMBER OF PRESCRIPTIONS** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **With Antibiotics** | **34** | **151** | **22.51%** |  |
| **2** | **Without Antibiotics** | **117** | **151** | **77.49%** |  |

**TABLE 7a – Nature of Prescriptions:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **NATURE OF PRESCRIPTIONS** | **NO OF PRESCRIPTIONS** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Prescription containing only generic drugs** | **4** | **151** | **2.64%** |  |
| **2** | **Prescription containing both generic drugs & trade names** | **147** | **151** | **97.36%** |  |

**TABLE 7b – Generic drug distribution:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Drug Type** | **NO OF DRUGS** | **TOTAL NO OF DRUGS**  **PRESCRIBED** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Generic Drug** | **509** | **1295** | **39.30%** |  |
| **2** | **Non-Generic Drug** | **786** | **1295** | **60.70%** |  |

**TABLE 8 – Injections prescribed:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **DRUG FORMULATION** | **NO OF DRUGS** | **TOTAL NO OF DRUGS**  **PRESCRIBED** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Injections** | **202** | **1295** | **15.6%** |  |
| **2** | **Without injections** | **1093** | **1295** | **84.4%** |  |

**TABLE 9 – Cost of drugs:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Drug Cost** | **No of drugs** | **TOTAL NO OF DRUGS**  **PRESCRIBED** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Free drugs** | **903** | **1295** | **69.72%** |  |
| **2** | **Paid drugs** | **392** | **1295** | **30.28%** |  |

**TABLE 10 – ATC/DDD CLASSIFICATION:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DRUG** | **ATC** | **PDD** | **DDD** | **PDD/DDD** |
| Isosorbide di nitrate | C01DA08 | 23.72 | 60mg O | 0.395 |
| Isosorbide mono nitrate | CO1DA14 | 20 | 40mg O | 0.5 |
| Glyceryl tri nitrate | CO1DA02 | 5.525 | 5mg O | 1.10 |
| Ranolazine | C01EB18 | 1000 | 1500mg O | 0.66 |
| Trimetazidine | C01EB15 | 45 | 40mg O | 1.125 |
| Aspirin | B01AC06 | 1 tablet | 1tablet O | 1 |
| Clopidogrel | B01AC04 | 75 | 75mg O | 1 |
| Heparin | B01AB01 | 15000 | 10000 U | 1.5 |
| Enoxaparin | B01AB05 | 8000 | 2000 U | 4 |
| Warfarin | B01AA03 | 5 | 7.5mg O | 0.66 |
| Enalapril | C09AA02 | 6.17 | 10mg O | 0.61 |
| Metoprolol (O) | C07AB02 | 16.761 | 150 mg O | 0.11 |
| Amlodipine | C08CA01 | 8.333 | 5mg O | 1.66 |
| Atenolol | C07AB03 | 45.83 | 75mg O | 0.611 |
| Telmisartan | C09CA07 | 53.33 | 40mg O | 1.33 |
| Atorvastatin | C10AA05 | 24.96 | 10mg O | 2.496 |
| Rosuvastatin | C10AA07 | 20 | 10mg O | 2 |
| Fenofibrate | C10AB05 | 145 | 200mg O | 0.725 |
| Furosemide (0) | C03CA01 | 39.09 | 40mg O | 0.977 |
| Furosemide (P) | C03CA01 | 54 | 40mg P | 1.35 |
| Spironolactone | C03DA01 | 55 | 75mg O | 0.733 |
| Torsemide | C03CA04 | 11 | 15mg O | 0.733 |
| Carvedilol | C07AG02 | 5.0781 | |  |  |  | | --- | --- | --- | | 37.5 mg O |  |  | | 0.13 |
| Digoxin (0) | C01AA05 | 0.23 | 0.25mg O | 0.92 |
| Nicorandil | C01DX16 | 7.5 | 40mg O | 0.18 |
| Trimetazidine | C01EB15 | 40 | 40mg O | 1 |
| Metformin | A10BA02 | 1044 | 2000 mg | 0.522 |
| Glimepiride | A10BA12 | 2.1764 | 2 mg O | 1.08 |

**TABLE 11 – DRUG TYPE DISTRIBUTION:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **DRUG TYPE** | **No of patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Anti-Anginal + Anti-Platelet** | **1** | **151** | **0.66%** |  |
| **2** | **Anti-Coagulant + Anti-Platelet** | **7** | **151** | **4.62%** |  |
| **3** | **Anti-Hypertensive + Anti-Anginal** | **1** | **151** | **0.66%** |  |
| **4** | **Anti-Hypertensive + Anti-Anginal + Anti-Platelet** | **49** | **151** | **32.45%** |  |
| **5** | **Anti-Hypertensive + Anti-Coagulant + Anti-Anginal + Anti-Platelet** | **12** | **151** | **7.95%** |  |
| **6** | **Anti-Hypertensive + Anti-Coagulant + Anti-Platelet** | **25** | **151** | **16.56%** |  |
| **7** | **Anti-Hypertensive + Anti-Platelet** | **37** | **151** | **24.50%** |  |
| **8** | **Anti-Hypertensive Only** | **3** | **151** | **1.99%** |  |
| **9** | **Anti-Platelet Only** | **15** | **151** | **9.95%** |  |
| **10** | **Nil** | **1** | **151** | **0.66%** |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **DRUG TYPE** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Anti-Diabetic + Hypo-Lipidemic** | **64** | **151** | **42.38%** |  |
| **2** | **Anti-Diabetic Only** | **10** | **151** | **6.62%** |  |
| **3** | **Hypo-Lipidemic Only** | **76** | **151** | **50.33%** |  |
| **4** | **Nil** | **1** | **151** | **0.66%** |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **DRUG TYPE** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Diuretics Only** | **32** | **151** | **21.19%** |  |
| **2** | **Heart Failure drugs** | **8** | **151** | **5.30%** |  |
| **3** | **Heart Failure drugs + Diuretics** | **17** | **151** | **11.26%** |  |
| **4** | **Nil** | **94** | **151** | **62.25%** |  |

**TABLE 10a – PRESCRIPTION PATTERN OF ANTI-PLATELETS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Anti-platelets** | **No of patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Aspirin alone** | **55** | **146** | **37.67%** |  |
| **2** | **Clopidogrel alone** | **15** | **146** | **10.27%** |  |
| **3** | **Aspirin + clopidogrel** | **76** | **146** | **52.06%** |  |

**TABLE 10b – PRESCRIPTION PATTERN OF ANTI-COAGULANTS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Anti-Coagulants** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
|  |
| **1** | **Heparin** | **21** | **44** | **47.73%** |  |  |
| **2** | **Enoxaparin** | **22** | **44** | **50.00%** |  |  |
| **3** | **Warfarin + Heparin** | **1** | **44** | **2.27%** |  |  |

**TABLE 10c – PRESCRIPTION PATTERN OF HYPOLIPIDEMIC DRUGS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Hypolipidemics** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
|  |
| **1** | **Atorvastatin** | **131** | **140** | **93.57%** |  |  |
| **2** | **Rosuvastatin** | **7** | **140** | **5.00%** |  |  |
| **3** | **Atorvastatin + Fenofibrate** | **2** | **140** | **1.43%** |  |  |

**TABLE 10d – PRESCRIPTION PATTERN OF ANTI-ANGINAL DRUGS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Anti-anginal drugs** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Isosorbide dinitrate** | **51** | **66** | **77.27%** |  |
| **2** | **Isosorbide mononitrate** | **1** | **66** | **1.52%** |  |
| **3** | **Nitroglycerine** | **8** | **66** | **12.12%** |  |
| **4** | **Ranolazine** | **1** | **66** | **1.52%** |  |
| **5** | **Trimetazidine** | **5** | **66** | **7.57%** |  |

**TABLE 10e – PRESCRIPTION PATTERN OF DIURETICS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Diuretics** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Inj.Furosemide** | **20** | **55** | **36.37%** |  |
| **2** | **T.Furosemide** | **22** | **55** | **40.00%** |  |
| **3** | **T.spironolactone** | **10** | **55** | **18.18%** |  |
| **4** | **T.Torsemide** | **3** | **55** | **5.45%** |  |

**TABLE 10f –** **PRESCRIPTION PATTERN OF HEART FAILURE DRUGS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Heart failure drugs** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **carvedilol** | **6** | **23** | **26.09%** |  |
| **2** | **Digoxin** | **6** | **23** | **26.09%** |  |
| **3** | **Carvedilol + Digoxin** | **2** | **23** | **8.70%** |  |
| **4** | **Ivabradine** | **3** | **23** | **13.03%** |  |
| **5** | **Nicorandil** | **6** | **23** | **26.09%** |  |

**TABLE 10g – PRESCRIPTION PATTERN OF ANTI-HYPERTENSIVE DRUGS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Anti-hypertensive drugs** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **ACE Inhibitors + Beta blockers** | **27** | **93** | **29.03** |  |
| **2** | **ACE inhibitors alone** | **41** | **93** | **44.09** |  |
| **3** | **Beta blocker alone** | **03** | **93** | **3.23** |  |
| **4** | **ARB alone** | **02** | **93** | **2.15** |  |
| **5** | **ARB + beta blockers** | **02** | **93** | **2.15** |  |
| **6** | **ARB +calcium channel blockers** | **05** | **93** | **5.38** |  |
| **7** | **Calcium channel blockers alone** | **04** | **93** | **4.30** |  |
| **8** | **ACE + calcium channel blockers** | **04** | **93** | **4.30** |  |
| **9** | **ACE + Beta blocker + Calcium channel blocker** | **03** | **93** | **3.23** |  |
| **10** | **Calcium channel blockers+ARB+Diuretic** | **01** | **93** | **1.08** |  |
| **11** | **ARB+calcium channel blocker+beta blocker** | **01** | **93** | **1.08** |  |

**TABLE 10h – PRESCRIPTION PATTERN OF ANTI-DIABETIC DRUGS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Anti-Diabetic** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Dapagliflozin + Glimepiride + Metformin + Vildagliptin** | **1** | **72** | **1.39%** |  |
| **2** | **Dapagliflozin only** | **1** | **72** | **1.39%** |  |
| **3** | **Glibenclamide + Metformin** | **1** | **72** | **1.39%** |  |
| **4** | **Gliclazide + Metformin** | **1** | **72** | **1.39%** |  |
| **5** | **Glimepiride + Metformin** | **12** | **72** | **16.67%** |  |
| **6** | **Glimepiride + Metformin + Pioglitazone + Voglibose** | **1** | **72** | **1.39%** |  |
| **7** | **Glimepiride + Metformin + Teneligliptin** | **1** | **72** | **1.39%** |  |
| **8** | **Glimepiride + Metformin + Voglibose** | **2** | **72** | **2.78%** |  |
| **9** | **Glipizide + Metformin** | **2** | **72** | **2.78%** |  |
| **10** | **Insulin** | **22** | **72** | **30.56%** |  |
| **11** | **Insulin + Dapagliflozin** | **1** | **72** | **1.39%** |  |
| **12** | **Insulin + Glimepiride + Metformin** | **1** | **72** | **1.39%** |  |
| **13** | **Insulin + Glimepiride + Metformin + Voglibose** | **1** | **72** | **1.39%** |  |
| **14** | **Insulin + Metformin** | **1** | **72** | **1.39%** |  |
| **15** | **Insulin + Vildagliptin** | **1** | **72** | **1.39%** |  |
| **16** | **Metformin Only** | **23** | **72** | **31.94%** |  |

**TABLE 10i – PATTERN OF ANTIBIOTIC DISTRIBUTION:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Antibiotic drugs** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Macrolide Antibiotics** | **05** | **43** | **11.62%** |  |
| **2** | **Nitroimidazoles** | **04** | **43** | **9.30%** |  |
| **3** | **Nitrofuran Antibiotics** | **02** | **43** | **4.65%** |  |
| **4** | **Penicillin antibiotics** | **04** | **43** | **9.30%** |  |
| **5** | **Fluroquinolones** | **03** | **43** | **7%** |  |
| **6** | **Cephalosporins** | **25** | **43** | **58.13%** |  |

**TABLE 10j – PRESCRIPTIONPATTERN OF MISCELLANEOUS DRUGS:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **MISCELLANEOUS DRUGS** | **No of Patients** | **TOT**  **AL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **Laxative + Sedative** | **7** | **138** | **5.07%** |  |
| **2** | **Laxative Only** | **4** | **138** | **2.90%** |  |
| **3** | **Peptic Ulcer Drugs + Laxative** | **9** | **138** | **6.52%** |  |
| **4** | **Peptic Ulcer Drugs + Laxative + Sedative** | **17** | **138** | **12.32%** |  |
| **5** | **Peptic Ulcer Drugs + Sedative** | **6** | **138** | **4.35%** |  |
| **6** | **Peptic Ulcer Drugs Only** | **23** | **138** | **16.67%** |  |
| **7** | **Sedative Only** | **2** | **138** | **1.45%** |  |
| **8** | **Vitamin + Peptic Ulcer Drug** | **2** | **138** | **1.45%** |  |
| **9** | **Vitamin + Peptic Ulcer Drug + Laxative** | **1** | **138** | **0.72%** |  |
| **10** | **Vitamin + Peptic Ulcer Drug + Laxative + Sedative** | **1** | **138** | **0.72%** |  |
| **11** | **Vitamin + Peptic Ulcer Drugs** | **43** | **138** | **31.16%** |  |
| **12** | **Vitamin + Peptic Ulcer Drugs + Laxative + Sedative** | **2** | **138** | **1.45%** |  |
| **13** | **Vitamin + Sedative** | **1** | **138** | **0.72%** |  |
| **14** | **Vitamin Only** | **20** | **138** | **14.49%** |  |

**TABLE 10k – ANTIHYPERTENSIVES IN PATIENTS WITH CAD WITHOUT CO-MORBIDITY :**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **S.no** | **Antihypertensives** | **No of Patients** | **TOTAL NO OF PATIENTS** | **PERCENTAGE** | **CHI-SQUARE TEST** |
| **1** | **ACE inhibitors alone** | **12** | **34** | **35.29%** |  |
| **2** | **ACE inhibitors + Betablockers** | **20** | **34** | **58.82%** |  |
| **3** | **Betablockers** | **02** | **34** | **5.89%** |  |